MedTrace Logo

A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

NCT07742098 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-08-03

No results posted yet for this study

Summary

This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

NTS-521

Intravenous NTS-521

OTHER

Placebo Control

0.9% saline solution delivered intravenously

Sponsors & Collaborators

  • NeuroTrauma Sciences, LLC

    lead INDUSTRY

Principal Investigators

  • Bijoy A Menon, MD · The University of Calgary Stroke Program & Stroke Clinical Trial Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2028-12-15
Completion
2028-12-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07742098 on ClinicalTrials.gov